NCT02316457View on ClinicalTrials.gov

RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 13, 2020

Study Completion Date

May 17, 2023

Conditions
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Interventions
BIOLOGICAL

IVAC_W_bre1_uID

vaccination

BIOLOGICAL

IVAC_W_bre1_uID/IVAC_M_uID

vaccination

Trial Locations (4)

55131

Johannes Gutenberg University, Mainz

65199

Dr. Horst Schmidt-Kliniken Wiesbaden, Wiesbaden

69120

National Center for Tumor Diseases (NCT), Heidelberg

75185

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
collaborator

Seventh Framework Programme

OTHER

lead

BioNTech SE

INDUSTRY